Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Group A streptococcal vaccines: Paving a path for accelerated development

Vaccine prevention of GAS infections and their immunological complications has been a goal of researchers for decades.

Research

Progress toward a global Group A streptococcal vaccine

The desire for an effective vaccine arises from the large burden of disease caused by the bacterium, particularly rheumatic fever and rheumatic heart disease.

Research

Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults

The objective of this tudy was to assess the reactogenicity of two 2010 trivalent inactivated influenza vaccine (TIV) formulations among adults, including...

Research

Influenza vaccine effectiveness against laboratory-confirmed influenza in healthy children aged 6-59 months:

The Western Australian Influenza Vaccine Effectiveness study commenced in 2008 to evaluate a new program to provide free influenza vaccine to all children...

Research

Vaccine Effectiveness Against Laboratory-confirmed Influenza in Healthy Young Children A Case-Control Study

The Western Australian Influenza Vaccine Effectiveness study commenced in 2008 to evaluate a new program to provide free influenza vaccine to all children...

Research

Assessing the protective effect of influenza vaccine against laboratory confirmed influenza in hospitalised children aged 6-59 months

Influenza vaccine was offered to all children aged 6-59 months resident in Western Australia in 2008, and we wished to evaluate the effectiveness of this immunisation programme.

News & Events

Warm Welcome for the Neonatal Infection and Immunity Team

Clinical Professor Tobias Strunk, Dr Andrew Currie and their Neonatal Infection and Immunity Team have become the newest members of the Wesfarmers Centre of Vaccines and Infectious Diseases.

Research

Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden

New malaria vaccine development builds on groundbreaking recommendations and roll-out of two approved pre-erythrocytic vaccines (PEVs); RTS,S/AS01 and R21/Matrix-M. Whilst these vaccines are effective in reducing childhood malaria within yearly routine immunization programs or seasonal vaccination, there is little evidence on how different PEV efficacies, durations of protection, and spacing between doses influence the potential to avert uncomplicated and severe childhood malaria. 

Research

Does adjunctive clindamycin have a role in Staphylococcus aureus bacteremia? A protocol for the adjunctive treatment domain of the S. aureus Network Adaptive Platform (SNAP) randomized controlled trial

The use of adjunctive antibiotics directed against exotoxin production in Staphylococcus aureus bacteremia (SAB) is widespread, and is recommended in many guidelines, but there is limited evidence underpinning this.

Research

Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization

WHO, as requested by its member states, launched the Expanded Programme on Immunization (EPI) in 1974 to make life-saving vaccines available to all globally. To mark the 50-year anniversary of EPI, we sought to quantify the public health impact of vaccination globally since the programme's inception.